| Literature DB >> 31408976 |
Alessandra Pino1, Nunziatina Russo1, Koenraad Van Hoorde2, Maria De Angelis3, Giuseppe Sferrazzo4, Cinzia Lucia Randazzo5, Cinzia Caggia1.
Abstract
Piacentinu Ennese is a protected designation of origin (PDO) cheese produced in the surrounding area of Enna (Sicily, Italy), using raw ewe's milk without the addition of any starter cultures. In the present study, the Lactobacillus population of Piacentinu Ennese PDO cheese was in vitro screened in order to select promising probiotic strains to be further used in humans. One hundred and sixty-nine lactic acid bacteria (LAB) were isolated from 90 days ripened cheeses and identified by Rep-PCR genomic fingerprinting, using the (GTG)5-primer, and by MALDI-TOF MS. One hundred and thirteen (113) isolates belonging to QPS-list species were characterized for both safety and functional properties. All tested isolates were considered safe because none showed either gelatinase, DNase, mucinase, or hemolytic activity. Tolerance to lysozyme, bile salts, and acidic conditions, along with ability to survive under simulated gastrointestinal digestion, were observed. In addition, based on antimicrobial activity against pathogens, cell surface characteristics, Caco-2 adhesion abilities, and anti-inflammatory potential, it was possible to confirm the strain-dependent functional aptitude, suggesting that Piacentinu Ennese PDO cheese may be considered a precious source of probiotic candidates.Entities:
Keywords: functional properties; lactic acid bacteria; safety assessment; traditional cheese
Year: 2019 PMID: 31408976 PMCID: PMC6723934 DOI: 10.3390/microorganisms7080254
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Figure 1UPGMA dendrogram of the polyphasic approach combining Rep-PCR and MALDI-TOF MS analyses of presumptive lactic acid bacteria (LAB) isolated from Piacentinu Ennese (PE) cheese samples. Node values indicate the average percentage of similarity based on (GTG)5-PCR and MALDI-TOF MS profiles. The tree was made with BioNumerics version 5.1.
Figure 2Occurrence of lysozyme tolerance among the screened strains (A) and its distribution within each species (B).
Figure 3Number of strains showing survival rates ≥80% or <80% after 2 and 4 h of incubation at pH 3.0 (A) and at pH 2.0 (B).
Figure 4Number of strains showing survival rates ≥80% or < 80% after treatment, for 2 and 4 h, with 0.5% (A) and 1.0% (B) of bile salts.
Survival (log CFU/mL) of the tested strains during in vitro gastrointestinal transit.
| Species | Strain | CI | SGJ | SIF |
|---|---|---|---|---|
| PE09 | 9.03 ± 0.11 | 5.30 ± 0.02 | 5.11 ± 0.02 | |
| PE11 | 9.12 ± 0.03 | 8.96 ± 0.06 | 8.84 ± 0.02 | |
| PE27 | 9.10 ± 0.07 | 8.02 ± 0.03 | 8.06 ± 0.06 | |
| PE30 | 9.01 ± 0.14 | 8.11 ± 0.02 | 8.01 ± 0.02 | |
| PE41 | 9.16 ± 0.02 | 4.98 ± 0.05 | 4.16 ± 0.03 | |
| PE42 | 9.28 ± 0.02 | 5.26 ± 0.08 | 5.15 ± 0.06 | |
| PE58 | 9.21 ± 0.05 | 5.02 ± 0.02 | 4.00 ± 0.03 | |
| PE66 | 9.22 ± 0.03 | 8.14 ± 0.06 | 8.03 ± 0.05 | |
| PE77 | 9.31 ± 0.06 | 5.31 ± 0.02 | 5.03 ± 0.08 | |
| PE92 | 9.24 ± 0.08 | 8.16 ± 0.02 | 8.11 ± 0.03 | |
| PE99 | 9.18 ± 0.05 | 9.01 ± 0.03 | 8.86 ± 0.06 | |
| PE101 | 9.20 ± 0.11 | 8.28 ± 0.04 | 8.14 ± 0.02 | |
| PE107 | 9.30 ± 0.13 | 4.05 ± 0.02 | 3.83 ± 0.02 | |
| PE115 | 9.12 ± 0.02 | 6.00 ± 0.06 | 5.84 ± 0.03 | |
| PE139 | 9.06 ± 0.12 | 4.21 ± 0.08 | 4.07 ± 0.10 | |
| PE141 | 9.19 ± 0.05 | 5.11 ± 0.02 | 5.03 ± 0.02 | |
| PE07 | 9.13 ± 0.04 | 8.12 ± 0.07 | 8.06 ± 0.08 | |
| PE08 | 9.11 ± 0.03 | 8.13 ± 0.04 | 8.02 ± 0.03 | |
| PE13 | 9.06 ± 0.07 | 8.01 ± 0.04 | 8.00 ± 0.02 | |
| PE25 | 9.14 ± 0.05 | 8.20 ± 0.06 | 8.15 ± 0.02 | |
| PE44 | 9.19 ± 0.07 | 8.01 ± 0.08 | 7.93 ± 0.06 | |
| PE61 | 9.10 ± 0.04 | 8.00 ± 0.05 | 7.96 ± 0.04 | |
| PE64 | 9.26 ± 0.06 | 8.87 ± 0.02 | 8.51 ± 0.04 | |
| PE81 | 9.23 ± 0.08 | 8.68 ± 0.02 | 8.05 ± 0.06 | |
| PE113 | 9.36 ± 0.04 | 4.88 ± 0.06 | 3.12 ± 0.04 | |
| PE137 | 9.07 ± 0.03 | 5.03 ± 0.06 | 4.91 ± 0.03 | |
| PE138 | 9.03 ± 0.11 | 5.21 ± 0.12 | 5.10 ± 0.07 | |
| PE151 | 9.23 ± 0.05 | 5.23 ± 0.11 | 5.06 ± 0.10 | |
| PE152 | 9.22 ± 0.07 | 9.04 ± 0.08 | 8.93 ± 0.06 | |
| PE14 | 9.15 ± 0.04 | 8.11 ± 0.03 | 8.04 ± 0.03 | |
| PE15 | 9.11 ± 0.03 | 8.02 ± 0.04 | 7.96 ± 0.06 | |
| PE16 | 9.23 ± 0.11 | 4.98 ± 0.07 | 4.33 ± 0.07 | |
| PE21 | 9.17 ± 0.06 | 9.03 ± 0.04 | 8.96 ± 0.07 | |
| PE38 | 9.11 ± 0.03 | 5.12 ± 0.08 | 4.91 ± 0.07 | |
| PE72 | 9.07 ± 0.08 | 8.03 ± 0.07 | 7.94 ± 0.08 | |
| PE73 | 9.09 ± 0.07 | 8.21 ± 0.06 | 8.07 ± 0.07 | |
| PE122 | 9.11 ± 0.06 | 8.18 ± 0.07 | 8.09 ± 0.04 | |
| PE123 | 9.16 ± 0.03 | 5.54 ± 0.08 | 5.31 ± 0.03 | |
| PE124 | 9.09 ± 0.06 | 8.86 ± 0.12 | 8.03 ± 0.06 | |
| PE159 | 9.21 ± 0.11 | 5.18 ± 0.14 | 5.03 ± 0.04 | |
| PE160 | 9.18 ± 0.04 | 8.07 ± 0.04 | 7.91 ± 0.07 | |
| PE96 | 9.16 ± 0.08 | 8.25 ± 0.02 | 8.13 ± 0.02 | |
| PE104 | 9.07 ± 0.02 | 8.15 ± 0.04 | 7.95 ± 0.03 | |
| PE120 | 9.30 ± 0.10 | 8.21 ± 0.03 | 8.02 ± 0.02 | |
| PE133 | 9.28 ± 0.02 | 5.24 ± 0.02 | 5.21 ± 0.04 | |
| PE135 | 9.18 ± 0.04 | 5.02 ± 0.02 | 4.56 ± 0.06 | |
| PE136 | 9.15 ± 0.06 | 4.34 ± 0.02 | 4.46 ± 0.02 | |
| PE04 | 9.16 ± 0.06 | 9.07 ± 0.06 | 8.94 ± 0.06 | |
| PE24 | 9.09 ± 0.07 | 8.24 ± 0.07 | 8.10 ± 0.03 | |
| PE85 | 9.13 ± 0.11 | 8.16 ± 0.14 | 7.98 ± 0.07 | |
| PE86 | 9.20 ± 0.07 | 8.83 ± 0.07 | 8.03 ± 0.14 | |
| PE102 | 9.14 ± 0.03 | 8.96 ± 0.07 | 8.84 ± 0.04 |
Cell density before transit (CI) and upon sequential exposure to simulated gastric juice (SGJ) and simulated intestinal fluid (SIF), determined by viable counting on Man, Rogosa and Sharpe (MRS) agar. Data are shown as mean log CFU/mL of three independent experiments and standard deviation.
Antimicrobial activity against food spoilage and pathogenic bacteria.
| Species | Strains | ||||
|---|---|---|---|---|---|
| PE44, PE61, PE25, PE13 | +++ | ++ | +++ | +++ | |
| PE64, PE08, PE81 | ++ | - | +++ | ++ | |
| PE07 | - | ++ | - | + | |
| PE152 | ++ | ++ | - | - | |
| PE14, PE15, PE21 | +++ | ++ | ++ | +++ | |
| PE72, PE73 | +++ | +++ | - | + | |
| PE124, PE160, PE122 | - | - | - | - | |
| PE30 | + | - | - | - | |
| PE92, PE101, PE11 | - | - | - | - | |
| PE66 | - | + | - | + | |
| PE09, PE27 | + | + | - | - | |
| PE24, PE85, PE86 | ++ | +++ | ++ | ++ | |
| PE04, PE102 | - | - | - | ||
| PE96, PE104 | - | - | - | - | |
| PE120 | - | - | - | - |
(-) no inhibition zone; (+) inhibition zone <10 mm; (++) inhibition zone 11–20 mm; (+++) inhibition zone > 20 mm.
Surface properties of the subset of 32 lactobacilli strains.
| Species | Strains | H% | Auto-A% | CoA% | ||
|---|---|---|---|---|---|---|
|
|
| |||||
|
| PE27 | 28.13 ± 0.54 a | 12.30 ± 0.19 a | 14.20 ± 0.20 c | 23.22 ± 0.21 e | 24.31 ± 0.26 e |
| PE30 | 31.09 ± 0.19 b | 53.13 ± 0.15 e | 21.47 ± 0.27 d | 32.54 ± 0.20 h | 12.25 ± 0.15 b | |
| PE92 | 41.21 ± 0.38 d | 56.30 ± 0.23 g | 46.18 ± 0.12 h | 14.38 ± 0.22 b | 37.17 ± 0.10 h | |
| PE101 | 36.30 ± 0.16 c | 58.41 ± 0.38 h | 31.48 ± 0.27 f | 23.20 ± 0.18 e | 28.63 ± 0.18 g | |
|
| PE07 | 43.12 ± 0.30 e | 74.11 ± 0.14 pq | 59.23 ± 0.07 no | 58.29 ± 0.24 p | 67.33 ± 0.18 r |
| PE13 | 71.36 ± 0.42 m | 77.41 ± 0.23 s | 51.29 ± 0.16 i | 60.33 ± 0.18 rr | 52.28 ± 0.13 i | |
| PE25 | 78.14 ± 0.13 q | 71.37 ± 0.28 n | 68.27 ± 0.16 r | 72.35 ± 0.19 v | 58.26 ± 0.15 m | |
| PE64 | 56.39 ± 0.33 l | 65.20 ± 0.20 l | 54.26 ± 0.13 l | 67.34 ± 0.27 s | 52.42 ± 0.14 i | |
| PE08 | 46.24 ± 0.31 f | 69.03 ± 0.23 m | 51.17 ± 0.12 i | 52.37 ± 0.15 m | 60.22 ± 0.19 o | |
| PE81 | 41.14 ± 0.37 d | 59.99 ± 0.27 i | 58.59 ± 0.20 n | 53.34 ± 0.24 n | 60.30 ± 0.20 o | |
| PE152 | 48.35 ± 0.35 g | 72.29 ± 0.09 o | 63.24 ± 0.18 p | 59.37 ± 0.28 q | 56.37 ± 0.22 l | |
| PE44 | 72.23 ± 0.20 mn | 71.47 ± 0.35 no | 72.35 ± 0.23 t | 51.41 ± 0.17 l | 58.64 ± 0.15 mn | |
| PE61 | 74.29 ± 0.26 no | 76.04 ± 0.34 r | 57.27 ± 0.16 m | 42.93 ± 0.32 i | 59.27 ± 0.23 n | |
|
| PE21 | 52.11 ± 0.10 i | 19.24 ± 0.17 c | 32.27 ± 0.16 g | 28.18 ± 0.12 f | 24.16 ± 0.12 e |
| PE72 | 56.33 ± 0.26 l | 15.16 ± 0.19 b | 14.20 ± 0.12 c | 29.34 ± 0.21 g | 21.73 ± 0.23 d | |
| PE73 | 48.22 ± 0.15 g | 23.38 ± 0.24 d | 6.35 ± 0.20 a | 12.18 ± 0.12 a | 18.71 ± 0.12 c | |
| PE124 | 46.35 ± 0.45 f | 54.61 ± 0.28 f | 23.40 ± 0.28 e | 18.21 ± 0.18 d | 26.74 ±0.22 f | |
| PE160 | 50.01 ± 0.53 h | 57.17 ± 0.13 g | 11.26 ± 0.16 b | 15.29 ± 0.24 c | 9.37 ± 0.20 a | |
|
| PE24 | 76.37 ± 0.35 p | 76.37 ± 0.24 r | 71.48 ± 0.21 s | 71.29 ± 0.18 u | 61.33 ± 0.11 p |
| PE85 | 73.25 ± 0.24 no | 73.23 ± 0.19 p | 66.34 ± 0.22 q | 69.27 ± 0.17 t | 71.19 ± 0.13 s | |
| PE86 | 74.33 ± 0.34 no | 74.36 ± 0.22 q | 59.60 ± 0.20 o | 56.39 ± 0.26 o | 63.28 ± 0.13 q | |
Results are expressed as average value and standard deviation of three separate experiments. Different letters in the same column indicate significant differences by one-way ANOVA test, followed by Tukey post-hoc test (P < 0.05). H%: Hydrophobicity; Auto-A%: Auto-aggregation; CoA%: Co-aggregation.
Figure 5Adhesion (%) of lactobacilli to Caco-2 cells. Data are the means from three independent experiments. Bars represent standard deviations. Letters a–p indicate P < 0.05.
Figure 6Lipid peroxidation inhibitory activity (Abs at 500 nm) in cell free supernatants (CFSs) of lactobacilli grown in MRS broth or un-inoculated and incubated MRS broth (control) for 24 h at 30 °C. The activity was measured under a linoleic acid oxidation system for 8 days. α-tocopherol (1 mg/mL) was used as the positive controls. Data are the means from three independent experiments. Bars represent standard deviations. Letters a–f indicate P < 0.05.
Gene levels expression in differentiated human macrophages.
| COX-1 | COX-2 | IL-8 | IL-10 | |
|---|---|---|---|---|
| LPS | 2.07 ± 0.10 | 15.22 ± 0.76 | 0.64 ± 0.03 | 128.50 ± 6.42 |
| PE13 | 34.31 ± 1.71 * | 3.24 ± 17.81 * | 1.42 ± 0.07 * | 103192 ± 5159 * |
| PE24 | 24.05 ± 1.20 * | 0.09 ± 0.004 * | 0.60 ± 0.03 | 615.96 ± 30.79 * |
| PE25 | 1.18 ± 0.21 | 2.28 ± 0.06 * | 0.003 ± 0.02 * | 9153 ± 12.1 * |
| PE44 | 0.42 ± 0.02 * | 2.41 ± 0.12 * | 0.0018 ± 9.27 × 10−5 * | 488 ± 0.24 * |
| PE61 | 0.002 ± 0.0001 * | 0.69 ± 0.03 * | 0.00053 ± 2.68 × 10−5 * | 797.55 ± 39.87 * |
| PE85 | 3.65 ± 0.18 * | 36.51 ± 1.82 * | 0.38 ± 0.019 | 3360.34 ± 168.01 * |
| PE86 | 2.28 ± 0.11 | 0.28 ± 0.01 * | 0.0018 ± 9.01 × 10−5 * | 1617.93 ± 80.89 * |
Data are presented as fold of increase respect to untreated cells, ± standard deviation. * P < 0.05 respect to lipopolysaccharide (LPS) treatment.